Trial of Controversial Alzheimer’s Drug Halted After Disappointing Results
Cassava Sciences said that its drug did not significantly reduce cognitive decline in 1,900 people with mild to moderate Alzheimer’s disease.
Cassava Sciences and its Alzheimer’s drug are done. The damage lingers
The Cassava Sciences story ended Monday exactly as many knew it would — with the company’s experimental drug for Alzheimer’s disease, simufilam, failing a clinical trial.
Cassava to stop trials of Alzheimer's drug after late-stage study failure
(Reuters) -Cassava Sciences said on Monday it will stop all trials of its Alzheimer's disease drug after it failed a late-stage study, sending shares of the drug developer plummeting more than 80% before the bell.
Cassava Sciences Stock Slides 84% as Alzheimer’s Trial Fails
Cassava Sciences stock collapsed after an Alzheimer’s drug the company was testing failed to significantly help participants in a clinical trial. The stock plummeted 84% to $4.15 Monday after reporting that a Phase 3 trial meant to demonstrate the efficacy of a medication called Simufilam fell short of key milestones.
Alector Therapeutics’ novel Alzheimer’s strategy fails in Phase 2 trial
Alector Therapeutics, working with AbbVie, was testing whether modulating immune cells in brain would slow Alzheimer's disease. Its drug failed the Phase 2 trial.
Cassava plummets 86% as simufilam phase 3 Alzheimer's trial misses endpoints
Cassava Sciences (NASDAQ:SAVA) stock has plummeted ~86% after announcing that Alzheimer's disease candidate simufilam did meet its co-primary endpoints in a phase 3 trial. Those endpoints were change in cognition and function from baseline to the end of week 52,
Cassava shares sink on plans to stop Alzheimer's drug studies
(Reuters) -Cassava Sciences said it will stop all trials of its Alzheimer's disease drug after it failed a late-stage study, ...
ScienceAlert on MSN5h
Nasal Spray May Slow Alzheimer's Disease, Study in Mice Suggests
The active agent in the nasal spray, 2-bromopalmitate, carries a high risk of interfering with a number of processes, making ...
FierceBiotech19h
Cassava flunks phase 3 Alzheimer's test, triggering early end of 2nd trial and stock crash
Cassava Sciences’ phase 3 Alzheimer’s disease trial has missed its co-primary endpoints. With the study also missing ...
Cassava's Alzheimer's drug fails in late-stage study
(Reuters) -Cassava Sciences on Monday said its experimental Alzheimer's disease drug did not meet the main or secondary goals ...
Science Daily8h
Alzheimer's: New strategy for amyloid diagnostics
To determine the diagnostic accuracy of the results of CSF tests compared to the gold standard PET imaging, the Munich researchers evaluated the data of over 400 patients with suspected Alzheimer's ...
Decoding Alzheimer’s: The Arctic Mutation’s Role in Unusual Brain Structures
Researchers have uncovered how certain genetic mutations lead to unique spherical amyloid plaques in inherited forms of ...
Lexington Herald Leader on MSN15h
Government must do a better job helping rural families with Alzheimer’s | Opinion
I’ve seen the devastating impact of Alzheimer’s disease in my family and my community. New treatments can slow down the ...
D. Boral says Anavex Alzheimer’s approach superior to Cassava
D. Boral Capital keeps a Buy rating on Anavex Life Sciences (AVXL) with a $46 price target after Cassava Sciences’ (SAVA) Phase 3 trial for ...
WTAJ Altoona on MSN9h
Alzheimer’s Foundation provides holiday travel tips for those with dementia
While everyone gears up for one of the busiest travel times of the year, the Alzheimer’s Foundation of America is offering ...
‘We’re living in uncertainty’: My sister has Alzheimer’s disease. How do I know the right time to take control of her finances?
Dear Quentin,  I have two sisters who have developed Alzheimer’s disease. My younger sister is actually more severely ...